Rituximab: perspective on single agent experience, and future directions in combination trials (Q34386171)

1 August 2017

1 reference

title

Rituximab: perspective on single agent experience, and future directions in combination trials (English)

1 reference

1 August 2017

1 reference

McLaughlin P

1

1 reference

1 August 2017

publication date

1 October 2001

1 reference

Critical Reviews in Oncology Hematology

1 August 2017

published in

1 reference

1 August 2017

volume

40

1 reference

1 August 2017

issue

1

1 reference

1 August 2017

page(s)

3-16

1 reference

Continuous cultures of fused cells secreting antibody of predefined specificity

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900130-5

7 January 2021

Treatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype Antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900130-5

7 January 2021

Replacing the complementarity-determining regions in a human antibody with those from a mouse

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900130-5

7 January 2021

The genetic engineering of monoclonal antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900130-5

7 January 2021

REMISSION INDUCTION IN NON-HODGKIN LYMPHOMA WITH RESHAPED HUMAN MONOCLONAL ANTIBODY CAMPATH-1H

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900130-5

7 January 2021

Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900130-5

7 January 2021

Immunotoxins: an update

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900130-5

7 January 2021

Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900130-5

7 January 2021

Immunotoxins: magic bullets or misguided missiles?

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900130-5

7 January 2021

A new era for radiolabeled antibodies in cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900130-5

7 January 2021

Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900130-5

7 January 2021

Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900130-5

7 January 2021

Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900130-5

7 January 2021

Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900130-5

7 January 2021

Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900130-5

7 January 2021

Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900130-5

7 January 2021

Growth inhibition of CD20-positive B lymphoma cell lines by IDEC-C2B8 anti-CD20 monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900130-5

7 January 2021

Cloning of the cDNA for a hematopoietic cell-specific protein related to CD20 and the beta subunit of the high-affinity IgE receptor: evidence for a family of proteins with four membrane-spanning regions

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900130-5

7 January 2021

Lymphoma-selective antibody Lym-1 recognizes a discontinuous epitope on the light chain of HLA-DR10.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900130-5

7 January 2021

Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900130-5

7 January 2021

CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900130-5

7 January 2021

IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900130-5

7 January 2021

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900130-5

7 January 2021

Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900130-5

7 January 2021

Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900130-5

7 January 2021

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900130-5

7 January 2021

Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a phase II trial of rituximab

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900130-5

7 January 2021

European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900130-5

7 January 2021

Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: high-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900130-5

7 January 2021

Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900130-5

7 January 2021

Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900130-5

7 January 2021

Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab)

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900130-5

7 January 2021

Levels of expression of CD19 and CD20 in chronic B cell leukaemias

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900130-5

7 January 2021

Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900130-5

7 January 2021

Rituximab: active treatment of central nervous system involvement by non-Hodgkin's lymphoma?

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900130-5

7 January 2021

Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900130-5

7 January 2021

bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900130-5

7 January 2021

Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900130-5

7 January 2021

Synergistic cytotoxicity of iodine-131-anti-CD20 monoclonal antibodies and chemotherapy for treatment of B-cell lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900130-5

7 January 2021

Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900130-5

7 January 2021

Attainment of molecular remission: a worthwhile goal?

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2801%2900130-5

7 January 2021

10.1016/S1040-8428(01)00130-5

Identifiers

DOI

1 reference

1 August 2017

1 reference